^(131)Ⅰ-KDR单克隆抗体抑制荷人膀胱癌SCID小鼠瘤体生长的实验研究

Growth suppression effect of ^(131)I-labeled anti-KDR monoclonal antibody on tumor tissue of human bladder cancer subcutaneously implanted in SCID mice

目的 探讨 1 31 Ⅰ标记抗KDR单抗对SCID小鼠人膀胱癌皮下移植瘤模型瘤体生长的抑制作用。方法 在复制SCID小鼠人膀胱癌皮下移植瘤模型的基础上 ,用1 31 Ⅰ标记抗KDR单抗 3G9,尾静脉注射荷瘤SCID小鼠作为实验组 ,以非标记抗KDR单抗 3G9及生理盐水尾静脉注射荷瘤SCID小鼠作为对照组及空白组 ,观察 1 31 Ⅰ标记抗KDR单抗对SCID小鼠人膀胱癌皮下移植瘤模型瘤体生长的抑制作用。结果 1 31 Ⅰ 3G9尾静脉注射荷瘤SCID小鼠后 3周 ,移植瘤瘤体内癌组织可见大片坏死 ,对照组移植瘤瘤体内癌组织也可见部分坏死 ,与空白组相比实验组与对照组对瘤体生长大小的抑制率分别为 96.8%和 87.7%。结论 1 31 Ⅰ

Objective To study the growth suppression effect of 131 I labeled anti KDR monoclonal antibody on the tumor tissue of human bladder cancer subcutaneously implanted in SCID mice. Methods The SCID murine model was established by subcutaneous implantation of human bladder cancer in mice. The 131 I labeled anti KDR monoclonal antibody (3G9) was injected into the caudal vein of mice (experimental group). The anti KDR monoclonal antibodies and saline were injected into the caudal vein of the mice (control group and blank group, respectively). The growth suppression effect of 131 I labeled anti KDR monoclonal antibody on the tumor tissue of SCID mice bearing human bladder cancer was observed. Results Tumor tissue necrosis was found in the mice of the experimental group and the control group at 3 weeks after the injection. Compared with that in the blank group, the growth suppression ratio in the experimental group and the control group were 96.8% and 87.7%, respectively. Conclusion 131 I labeled anti KDR monoclonal antibody may be of potential clinical significance in the anti angiogenesis therapy for human cancer.